Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model

被引:362
作者
Kaplan-Lefko, PJ
Chen, TM
Ittmann, MM
Barrios, RJ
Ayala, GE
Huss, WJ
Maddison, LA
Foster, BA
Greenberg, NM
机构
[1] Dept Mol & Cellular Biol, Houston, TX 77030 USA
[2] Scott Dept Urol, Houston, TX USA
[3] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA
[4] Houston Dept Vet Affairs Med Ctr, Houston, TX USA
[5] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA
关键词
TRAMP; pathology; prostate cancer; pre-clinical trials;
D O I
10.1002/pros.10215
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. Animal models that closely mimic clinical disease can be exploited to hasten the pace of translational research. To this end, we have defined windows of opportunity in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model of prostate cancer as a paradigm for designing pre-clinical trials. METHODS. The incidence of cancer, metastasis, and distribution of pathology were examined as a function of time in TRAMP mice. The expression of various markers of differentiation were characterized. RESULTS. The TRAMP model develops progressive, multifocal, and heterogeneous disease. Each lobe of the prostate progressed at a different rate. Cytokeratin 8, E-cadherin, and androgen receptor (AR) were expressed during cancer progression but levels were reduced or absent in late stage disease. A distinct epithelial to neuroendocrine (ENT) shift was observed to be a stochastic event related to prostate cancer progression in TRAMP. CONCLUSIONS. This study will serve as the basis for the rational design of pre-clinical studies with genetically engineered mouse models. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:219 / 237
页数:19
相关论文
共 49 条
  • [1] Abate-Shen Cory, 2002, Trends Genet, V18, pS1, DOI 10.1016/S0168-9525(02)02683-5
  • [2] Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma
    Bollito, E
    Berruti, A
    Bellina, A
    Mosca, A
    Leonardo, E
    Tarabuzzi, R
    Cappia, S
    Mari, M
    Tampellini, M
    Fontana, D
    Gubetta, L
    Angeli, A
    Dogliotti, L
    [J]. ANNALS OF ONCOLOGY, 2001, 12 : S159 - S164
  • [3] Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status
    Bonkhoff, H
    [J]. ANNALS OF ONCOLOGY, 2001, 12 : S141 - S144
  • [4] BOSTWICK DG, 1987, CANCER, V59, P788, DOI 10.1002/1097-0142(19870215)59:4<788::AID-CNCR2820590421>3.0.CO
  • [5] 2-I
  • [6] Bcl-2 accelerates multistep prostate carcinogenesis in vivo
    Bruckheimer, EM
    Brisbay, S
    Johnson, DJ
    Gingrich, JR
    Greenberg, N
    McDonnell, TJ
    [J]. ONCOGENE, 2000, 19 (46) : 5251 - 5258
  • [7] CATALONA WJ, 1994, NEW ENGL J MED, V331, P996
  • [8] Cox ME, 1999, CANCER RES, V59, P3821
  • [9] E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens
    De Marzo, AM
    Knudsen, B
    Chan-Tack, K
    Epstein, JI
    [J]. UROLOGY, 1999, 53 (04) : 707 - 713
  • [10] Interleukin-6-and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells
    Deeble, PD
    Murphy, DJ
    Parsons, SJ
    Cox, ME
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (24) : 8471 - 8482